Guy Brannon, MD
Psychiatry · Shreveport, LANPI 1164481875
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 357 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,745, more than ten times the $66 reported in 2019. Among psychiatry clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 357 payments — averaging $18.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$975
- AbbVie$900
- Alkermes, Inc.$823
- Neurocrine Biosciences, Inc.$526
- Lundbeck LLC$517
- Johnson & Johnson$473
- plus $2K from 15 others
Across 180 payments — averaging $7540.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$664K
- AbbVie$501K
- Sunovion Pharmaceuticals Inc.$119K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$33K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$18K
- Sumitomo Pharma America, Inc.$12K
- plus $10K from 3 others
What the payments were for
- Food & beverage$6,23797%
- Education$2063%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 47 | $975 |
| AbbVie(2 entities) | 66 | $900 |
| Alkermes, Inc. | 41 | $823 |
| Neurocrine Biosciences, Inc. | 43 | $526 |
| Lundbeck LLC | 24 | $517 |
| Johnson & Johnson | 20 | $473 |
| Otsuka America Pharmaceutical, Inc. | 24 | $420 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 22 | $417 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $292 |
| Indivior Inc. | 8 | $191 |
| E.r. Squibb & Sons, L.L.C. | 11 | $174 |
| Braeburn Inc. | 7 | $149 |
| Livanova USA, Inc. | 3 | $118 |
| Axsome Therapeutics, Inc. | 5 | $106 |
| Vanda Pharmaceuticals Inc. | 4 | $103 |
| Ironshore Pharmaceuticals Inc. | 4 | $89 |
| Sunovion Pharmaceuticals Inc. | 5 | $62 |
| Bioxcel Therapeutics, Inc. | 2 | $40 |
| Collegium Pharmaceutical, Inc. | 2 | $32 |
| Supernus Pharmaceuticals, Inc. | 1 | $24 |
| Almatica Pharma LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$480
- INVEGA SUSTENNA$125
How this compares
$6,443 in reported general payments places this provider in the 90th percentile of 474 psychiatry providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Paliperidone ErPaliperidone | 26 | $3,705 |
| Quetiapine Fumarate | 87 | $1,815 |
| Oxcarbazepine | 29 | $1,233 |
| Gabapentin | 61 | $792 |
| Divalproex Sodium | 35 | $722 |
| Ziprasidone Hcl | 16 | $584 |
| Trazodone Hcl | 46 | $552 |
| Aripiprazole | 18 | $516 |
| Olanzapine | 31 | $463 |
| Mirtazapine | 26 | $452 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $416 |
| Divalproex Sodium ErDivalproex Sodium | 16 | $381 |
| Methylphenidate Hcl | 12 | $376 |
| Prazosin Hcl | 21 | $311 |
| Risperidone | 27 | $304 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Almatica Pharma LLCSertraline Hcl | $14 | $14731 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 474 psychiatry providers in Louisiana.
Other psychiatry in Shreveport
- Gregory BrownShreveport$495K
- Jasjit SinghShreveport$420K
- Suresh SabbenahalliShreveport$10K
- Christopher BernadasShreveport$6K
- Daniel FeeneyShreveport$5K
- Patrick HayesLake Charles$837K
- Maria CruseThibodaux$522K
- Larry WarnerBaton Rouge$495K
- Arwen PodestaNew Orleans$466K
- Roger BrownMandeville$216K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.